LO capa FOLDER ASCO 2009

Hospital de Clínicas de Porto Alegre (HCPA/UFRGS)
Instituto Nacional do Câncer (INCA)
Sociedade Brasileira de Oncologia Clínica (SBOC)
Fundação Oswaldo Cruz (FIOCRUZ)
Academia Nacional de Medicina (ANM)
Academia Sul-Rio-Grandense de Medicina (ASRM)
Sociedade Brasileira de Cancerologia (SBC)
Sociedade Franco Brasileira de Oncologia (SFBO)
Sindicato Médico do Rio Grande do Sul
Conselho Regional de Medicina do Rio Grande do Sul
Secretaria Estadual de Ciência e Tecnologia, RS (SECT-RS)
Informações e Gerenciamento
Agência de Turismo Oficial
51 3216 6300
www.felliniturismo.com.br
www.ccmeventos.com.br/soad2009
Apoio
2111/03-DR/RS
CCM EVENTOS
Patrocínio
Programa Preliminar
Realização
11 de Setembro | Sexta-feira | Manhã
General Session I: Genitourinary Cancers
8:15 | 9:45
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients
with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.
Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or
5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial).
Preoperative fluorouracil (FU)-based chemoradiation with and without weekly
oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio
Terapia Adiuvante Retto (STAR)-01 randomized phase III trial.
Final results of the phase III, randomized, double-blind AVOREN trial of first-line
bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC).
Discussion: Andrés Cervantes (SPAIN)
A randomized, double-blind phase III study of pazopanib in treatment-naive and
cytokine-pretreated patients with advanced renal cell carcinoma (RCC).
General Session III: Gastrointestinal
Cancers (Gastric & Anal Cancers)
Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate
cancer (CRPC).
Discussion: Nancy Dawson (USA)
9:45 Invervalo
General Session II: Gastrointestinal
Cancers
11:15 | 12:30 Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard
chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)positive advanced gastric cancer (GC).
Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma
of the stomach and cardia: Randomized EORTC phase III trial #40954.
A randomized trial of chemoradiation using mitomycin or cisplatin, with or without
maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II).
10:00 | 11:15
Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy
(CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced
rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.
Discussion: Andrés Cervantes (SPAIN)
12:30 | 13:30
Simpósio Satélite Novartis
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III
carcinoma of the colon: Results of NSABP Protocol C-08.
2
3
11 de Setembro | Sexta-feira | Tarde
General Session IV: Gastrointestinal (Pancreas & Hepatobiliary Tract)
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with
newly diagnosed diffuse large B-cell non-Hodgkin’s lymphoma.
13:30 | 15:15
R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma
(DLBCL) followed by autologous stem cell transplantation: CORAL study.
A prospective, randomized trial of chemotherapy with or without the low molecular
weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer
(APC): Results of the CONKO 004 trial.
Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic
biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK
ABC-02 trial).
Placebo-controlled, double-blind, prospective, randomized study of the effect
of octreotide LAR in the control of tumor growth in patients with metastatic
neuroendocrine midgut tumors: A report from the PROMID study group.
Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate
(ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or
refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL).
Discussion: Santiago Pavlovsky (ARGENTINA)
17:00 Invervalo
General Session VI: Head & Neck cancers
ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase
III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in
patients with resected pancreatic ductal adenocarcinoma.
Discussion: Jorge Gallardo (CHILE)
15:15 Invervalo
General Session V: Lymphoma
15:30 | 17:00
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission:
Phase III clinical trial results.
17:15 | 18:30
Final results of a randomized phase III trial comparing induction chemotherapy with
cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus
CRT alone as first-line treatment of unresectable locally advanced head and neck cancer
(LAHNC).
Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with
primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the
DAHANCA 10 trial.
Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV
oropharyngeal cancer (OPC) in RTOG 0129.
Discussion: Christian Domenge (FRANCE)
4
5
12 de Setembro | Sábado | Manhã
General Session VII: Breast Cancer
– Local/Regional and Adjuvant Therapy
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of
chemotherapy with or without bevacizumab (B) for first-line treatment of HER2negative locally recurrent or metastatic breast cancer (MBC).
8:15 | 10:00
Impact of omission of completion axillary lymph node dissection (cALND) or axillary
radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or
isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the
MIRROR study.
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC),
in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.
Discussion: Reinaldo Chacón (ARGENTINA)
Factors associated with bilateral versus single mastectomy in a diverse, populationbased sample of breast cancer patients.
General Session IX: Breast Cancer
– New Drug Therapies
Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by
4-cycle taxane with 8-cycle taxane as adjuvant therapy for node-positive breast cancer:
Results of N-SAS-BC02 trial.
11:30 | 12:30
Value of adjuvant radiation therapy in breast cancer patients with one to three positive
lymph nodes undergoing a modified radical mastectomy and systemic therapy.
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and
paclitaxel: The I-SPY TRIAL
Discussion: José Bines (BRAZIL)
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination
with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast
cancer (TNBC): Results of a randomized phase II trial.
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast
cancer.
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced
ovarian cancer.
10:00 Invervalo
Discussion: Sérgio Simon (BRAZIL)
General Session VIII: Breast Cancer
– Metastatic
Simpósio Satélite Schering-Plough
12:30 | 13:30
Novas perspectivas para o tratamento de câncer de ovário recorrente
10:30 | 11:30
6
Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus
docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast
cancer (MBC).
7
12 de Setembro | Sábado | Tarde
General Session X: Gynecological Cancers
13:30 | 15:30 Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin
(CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the
MITO-2 randomized multicenter trial.
A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin
versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC):
CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).
A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102):
Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line
treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients.
A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125
level alone versus delayed treatment based on conventional clinical indicators (MRC
OV05/EORTC 55955 trials).
A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and
radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in
patients with stage IIB to IVA carcinoma of the cervix.
Discussion: Carlos Vallejos Sologuren (PERU)
MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer.
Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women
in the Women’s Health Initiative randomized clinical trial.
SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus
placebo following nonprogression with first-line platinum-based chemotherapy in
patients with advanced NSCLC.
Discussion: Renato Martins (USA)
General Session XII
17:00 | 18:15
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung
cancer (NSCLC): Data from the FLEX study.
Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac)
plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing
bevacizumab (B) therapy with or without erlotinib (E) after completion of
chemotherapy with B for first-line treatment of locally advanced, recurrent, or
metastatic non-small cell lung cancer (NSCLC).
15:15 Invervalo
General Session XI: Lung Cancer
Discussion: Renato Martins (USA)
15:30 | 17: 00 8
Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy
followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage nonsmall cell lung cancer (NSCLC): Results of the NATCH multicenter, randomized phase III
trial.
9
OBJETIVOS
Oferecer uma oportunidade aos médicos oncologistas
do Brasil e da América Latina de familiarizarem-se com
os melhores trabalhos e resultados de pesquisas de novos
tratamentos do câncer, apresentados durante o Encontro
Convidados
internacionais
Andrés Cervantes (Espanha)
2008 da ASCO, participar de sessões educacionais e atividades
Carlos Vallejos (Peru)
“Fale com o Professor”, com eminentes especialistas de cada
Eduardo Cazap (Argentina)
área. Por se tratar de uma imersão de dois dias inteiros, os
Jorge Gallardo (Chile)
participantes também serão beneficiados por discussões
informais com os membros do corpo docente.
Nancy Dawson (Estados Unidos)
Reinaldo Chacón (Argentina)
PURPOSE
To provide an opportunity for Latin American medical
oncologists to be exposed to the best papers presented during
the 2008 ASCO meeting, to attend educational and “meet-theprofessor” sessions with top quality experts in the field. Being
a two-day “full immersion” scientific activity, the audience will
also benefit from informal discussions with faculty members.
10
Renato Martins (Estados Unidos)
Santiago Pavlovsky (Argentina)
es
d
a
d
i
v
o
n
s
a
Acompanhe ção científica
da programa evento!
pelo site do